The authors found no significant increase in the LLA for SGLT2 inhibitors compared to GLP-1 RAs, while they were associated with a lower risk compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, but a higher risk compared to sulphonylureas [99]
[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Heymsfield SB, Yang S, McCarthy C, et al
doi: 10.3389/FENDO.2017.00098 70 CaiTTLiHQJiangLLWangHYLuoMHSuXFet al
In addition, the article reviews the clinical progress of GLP-1R agonists, including their efficacy, safety and potential in the treatment of diabetes and related complications
It, however, remains controversy on exactly how these drugs access their targets in the brain
Approval was granted on the basis that it had been shown to achieve a weight loss of over 25 percent or more in over a third of the participants in clinical trials